<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059123</url>
  </required_header>
  <id_info>
    <org_study_id>P071207</org_study_id>
    <secondary_id>2008-006794-32</secondary_id>
    <nct_id>NCT01059123</nct_id>
  </id_info>
  <brief_title>Short Course of Amoxicillin for Erysipelas</brief_title>
  <acronym>SHARE</acronym>
  <official_title>Randomized Non Inferiority Study Comparing Short Course of Oral Amoxicillin to One of the Usual Treatments of Lower Leg Erysipelas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société de Dermatologie Française</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The propose of this study is to determine whether a 6-day duration of oral amoxicillin
      treatment of erysipelas is non-inferior to a 14-day standard duration intravenous then oral
      amoxicillin regimen. This trial will be open but evaluation will be perform by a blind
      evaluator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To fight against increasing rate of bacterial resistance to antibiotics, several studies have
      demonstrated efficacy of short antibiotic course in e.g. acute streptococcal tonsillitis,
      community acquired pneumonia, and urinary tract infection. Erysipelas is an acute
      dermo-hypodermal infection due to streptococcus. To date no resistance of theses bacteria to
      amoxicillin was described. The diagnosis of erysipelas is clinical. Thus, short course of
      antibiotic is a good regimen to test in erysipelas treatment. To date there is no controlled
      trial concerning efficacy of oral amoxicillin in erysipelas treatment. Expected advantages of
      the demonstration of the non inferiority of a short and oral amoxicillin treatment in
      erysipelas are: reduction of antibiotic selective pressure, cost, adverse events caused by
      infusion and hospitalisation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient number of inclusion
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate defined as body temperature ≤ 37,5°and disappearance of the cutaneous plaque (score=o)</measure>
    <time_frame>Day 30 ± 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to obtain disappearance of fever and local signs</measure>
    <time_frame>up to day 30 ± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>end of treatment to day 30± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>day 30± 5 to day 95± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>30 days ± 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Erysipelas</condition>
  <arm_group>
    <arm_group_label>1:Short treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:Usual treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>50 mg/kg/24H ; Per Os ; 3 times/day 6 days</description>
    <arm_group_label>1:Short treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.</description>
    <arm_group_label>2:Usual treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 18 years of age

          -  First episode of erysipelas of a lower leg defined as

               -  acute well delineate inflammation than had lasted less than 5 days

               -  T°≥ 38°5 at least once during the past 5 days or chills.

               -  Score ≥3 : oedema, erythema, pain each scored from 0 to 3 : 0= none, 1= moderate,
                  3= severe

          -  Written informed consent provided by the patient

          -  available health insurance

          -  accept conditions of the trial

        Exclusion Criteria:

          -  Erysipelas for more than 5 days

          -  Score &lt; 3

          -  Septic shock

          -  Clinical signs of necrotizing cellulitis or fasciitis, bullous lesions related to
             necrosis, purpuric lesions or superficial cutaneous necrosis.

          -  Past history of erysipelas of the same lower leg

          -  Erysipelas not on the lower leg

          -  Bilateral erysipelas

          -  Bite occuring during the preceding 7 days.

          -  Diabetic foot

          -  patients who have previously received systemic antibiotherapy within the last 5 days
             (except one or two doses within last 24 hours)

          -  History of any hypersensitivity or allergic reaction to beta-lactam drugs

          -  Known renal or Hepatic failure

          -  Known HIV infection

          -  Female patients who are pregnant, lactating (breast milk feeding), or who are of child
             bearing potential and not using an acceptable method of birth control

          -  Impossibility to stop immunosuppressive treatment, systemic corticosteroids or
             nonsteroidal anti-inflammatory drugs.

          -  Severe gastrointestinal disease, dysphagia or any pathology preventing oral
             administration of treatment.

          -  Denied to sign written informed consent

          -  Unable or unwilling to adhere to the study-specified procedures and restrictions

          -  Evolutive cancer under treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHOSIDOW, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Service de dermatologie</name>
      <address>
        <city>Créteil</city>
        <state>Ile de France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amoxicillin</keyword>
  <keyword>Erysipelas</keyword>
  <keyword>Short course</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erysipelas</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

